Table 1
From: Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy
| Â | MEL (N=107) | NSCLC (N=129) | RCC (N-34) | |||
|---|---|---|---|---|---|---|
Dose (mg/kg) | ORR % (n/N) | PFS 24 wks, % | ORR % (n/N) | PFS 24 wks, % | ORR % (n/N) | PFS 24 wks, % |
0.1 | 35 (6/17) | 41 | - | - | - | - |
0.3 | 28 (5/18) | 35 | - | - | - | - |
1 | 31 (11/35) | 51 | 3 (1/33) | 26 | 28 (5/18) | 50 |
3 | 41 (7/17) | 55 | 24 (9/37) | 40 | - | - |
10 | 20 (4/20) | 35 | 20 (12/59) | 33 | 31 (5/16) | 67 |